In our joint webinar with Dotmatics, Julie Morrison and Steve Manning explain how the digitalized lab of the future integrates all aspects of the drug discovery pipeline to bring therapeutics to market faster.
Don’t worry if you missed it, it’s also available On-Demand!
No time to watch? Keep reading for a quick recap.
The current methods used to manage in vivo studies are no longer effective and return on investment for drug discovery R&D has been steadily decreasing. At the same time, the average cost of bringing a drug to market has grown to approximately 2 billion dollars and can take over a decade to complete. Digitalizing drug discovery allows integration across departments and time-zones, enabling researchers to explore and search data upstream and downstream with visibility into operations and chain of custody.
Using two fictional companies as examples, Julie and Steve compare how each company would handle set-backs during the drug discovery process.
Remnant Labs has already implemented a comprehensive digital platform like Climb/Dotmatics.
When issues such as looking up historical data, contamination, and major disaster strike Remnant is able to utilize their data storage and management solution to quickly overcome these problems and move forward with their research. Hydra is stuck repeating work; wasting time and resources.
Hydra, realizing they are behind the curve and need to adopt digitalization if they want to stay competitive, start the process of onboarding their own drug discovery platform. It turns out digitalization is easier than they think!
